Press Releases

< 2021 >

Filter:

September 28, 2021
Genocea to Present at Upcoming Conferences
CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical compa...
September 13, 2021
Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences' Board of Directors
CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical compa...
September 7, 2021
Genocea to Present at Upcoming Scientific and Investor Conferences
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical compa...
July 29, 2021
Genocea Provides Second Quarter 2021 Corporate Update
GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues GEN-009 neoantigen vaccine candidate show...
July 22, 2021
Genocea to Host Second Quarter 2021 Corporate Update Conference Call & Webcast
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical compan...
July 13, 2021
Genocea Doses First Patient in Phase 1/2a TiTAN Clinical Trial for GEN-011 Neoantigen-Targeted T cell Therapy
CAMBRIDGE, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical compan...
June 4, 2021
Genocea Presents Promising Long-term Results from GEN-009 Neoantigen Vaccine Phase 1 Trial at ASCO 2021
Four of nine checkpoint inhibitor-sensitive patients experienced RECIST responses post vaccination; median duration with...
April 29, 2021
Genocea Provides First Quarter 2021 Corporate Update
GEN-011 and GEN-009 immuno-oncology programs continue to advance Research on Inhibigens ™ and SARS-CoV-2 continues to pr...
April 22, 2021
Genocea To Host First Quarter 2021 Corporate Update Conference Call & Webcast
CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical compa...
April 10, 2021
Genocea to Present Novel Preclinical Inhibigen™ Data at AACR Annual Meeting 2021
Pro-tumor effects detected as early as four days after Inhibigen administration Insights into Inhibigen biology may yiel...
April 6, 2021
Genocea to Present at the 20th Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical compa...
March 2, 2021
Genocea to Present at the H.C. Wainwright Global Life Sciences Conference
CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical compa...
February 11, 2021
Genocea Provides Fourth Quarter 2020 Corporate Update
GEN-011 and GEN-009 clinical trials continue to advance ATLAS TM stimulatory antigen and inhibitory antigen (Inhibigen T...
February 4, 2021
Genocea to Host Fourth Quarter 2020 Corporate Update Conference Call & Webcast
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical compan...
January 28, 2021
Genocea Announces Publication in Cancer Discovery Highlighting the Advantages of Neoantigen Identification with the ATLAS™ Platform
Study validates ATLAS bioassay for developing patient-specific cancer immunotherapies by including neoantigens of anti-t...
January 19, 2021
Genocea to Participate in the B. Riley Securities’ Virtual Oncology Investor Conference
CAMBRIDGE, Mass. , Jan. 19, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical compa...
January 4, 2021
Genocea to Present at the H.C. Wainwright Virtual BioConnect Conference
CAMBRIDGE, Mass. , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.  (NASDAQ: GNCA), a biopharmaceutical comp...